Tag Archives: NIH

Bayh-Dole preempts NIH policy on improper financial gain

Here’s a passage from the NIH Grants Policy Statement (Part I, Chapter 4): NIH grants are subject to requirements intended to ensure that recipient organizations handle their Federal awards responsibly. Recipients are required to adopt and enforce policies that minimize … Continue reading

Posted in Bayh-Dole, Policy | Tagged , , , | Comments Off on Bayh-Dole preempts NIH policy on improper financial gain

Exceptional Circumstances in Bayh-Dole, 6

You may think it’s mean of me to pick on Dr. Thomas for a talk that’s a decade old, and presented before the Stanford v Roche case was decided. If so, then you might want to consider the Public Health … Continue reading

Posted in Bayh-Dole | Tagged , , , | Comments Off on Exceptional Circumstances in Bayh-Dole, 6

Exceptional Circumstances in Bayh-Dole, 2

Here’s the slide from Dr. Thomas that starts our descent into darkness. Part of the slide contents is accurate. Part is slipped. Let’s take up the slipped. First, Bayh-Dole does not say the federal government “retains patent rights” when the … Continue reading

Posted in Bayh-Dole, Technology Transfer | Tagged , , , | Comments Off on Exceptional Circumstances in Bayh-Dole, 2

Exceptional Circumstances in Bayh-Dole, 1

In 2008, Dr. Jeffrey W. Thomas, then a senior advisor to the Technology Transfer Center at the National Cancer Institute, gave a talk on Bayh-Dole’s exceptional circumstances. The slide deck is still up at a federal laboratory consortium web site. … Continue reading

Posted in Bayh-Dole | Tagged , , , | Comments Off on Exceptional Circumstances in Bayh-Dole, 1

The NIH’s View of Bayh-Dole Compliance, 8

We are working through the NIH’s policy manual on Bayh-Dole. We reach a helpful list. Some of the steps required by the regulation to retain intellectual property rights to subject inventions include: Report all subject inventions to NIH. Make efforts … Continue reading

Posted in Bayh-Dole | Tagged , , , | Comments Off on The NIH’s View of Bayh-Dole Compliance, 8

The NIH’s View of Bayh-Dole Compliance, 7

We have come full circle through NIH’s garbled version of Bayh-Dole, having been referred by the NIH’s SBIR guidance back to the NIH’s policy manual regarblization of Bayh-Dole in section 8.2.4. Section 8.2 has a bunch of data and research … Continue reading

Posted in Bayh-Dole | Tagged , , | Comments Off on The NIH’s View of Bayh-Dole Compliance, 7

The NIH’s View of Bayh-Dole Compliance, 6

Research Enterprise has been examining the NIH’s representation of Bayh-Dole. So far we have seen that the NIH persists in citing a 1995 document that gives “guidance” that the Supreme Court in Stanford v Roche (2011) rejected. But the NIH … Continue reading

Posted in Bayh-Dole | Tagged , , , , | Comments Off on The NIH’s View of Bayh-Dole Compliance, 6

The NIH’s View of Bayh-Dole Compliance, 5

We are working NIH’s not so tasty guidance to participants in its SBIR and STTR programs directed at small businesses. We reach the NIH’s account of the “principal features” of Bayh-Dole, at least with regard to “intellectual property” requirements: Principal … Continue reading

Posted in Bayh-Dole | Tagged , , , , , | Comments Off on The NIH’s View of Bayh-Dole Compliance, 5

The NIH’s View of Bayh-Dole Compliance, 4

Here’s the NIH offering an overview of Bayh-Dole for its SBIR and STTR programs. Much of the “information” here appears to be drawn from an NIH Q&A document from 1995. That document, “A ’20-20′ View of Invention Reporting to the … Continue reading

Posted in Bayh-Dole | Tagged , , , | Comments Off on The NIH’s View of Bayh-Dole Compliance, 4

The NIH’s View of Bayh-Dole Compliance, 3

We are working through NIH guidance on Bayh-Dole reporting requirements. In the process we are making note about how thoroughly NIH misrepresents Bayh-Dole. Sloppy? Indifferent? Does it matter? The next bit is going to be a bother: If it helps, … Continue reading

Posted in Bayh-Dole | Tagged , , | Comments Off on The NIH’s View of Bayh-Dole Compliance, 3